Glaxo Gets FDA Breakthrough Therapy Label For Bone Marrow Treatment
LONDON (Alliance News) - GlaxoSmithKline PLC said Monday that it had received Breakthrough Therapy designation for its bone marrow disorder treatment Promacta/Revolade from the US Food and Drug Administration. The treatment is designed for patients with severe aplastic anemia, a rare disord
Read more